MX2021016049A - Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas. - Google Patents

Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.

Info

Publication number
MX2021016049A
MX2021016049A MX2021016049A MX2021016049A MX2021016049A MX 2021016049 A MX2021016049 A MX 2021016049A MX 2021016049 A MX2021016049 A MX 2021016049A MX 2021016049 A MX2021016049 A MX 2021016049A MX 2021016049 A MX2021016049 A MX 2021016049A
Authority
MX
Mexico
Prior art keywords
methods
pancreatic cancer
treatment
rad51 inhibitors
rad51
Prior art date
Application number
MX2021016049A
Other languages
English (en)
Inventor
Alfredo C Castro
Joseph VACCA
Melinda Day
Casey Cameron Mccomas
Tyler Maclay
Kevin Mills
Original Assignee
Cyteir Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyteir Therapeutics Inc filed Critical Cyteir Therapeutics Inc
Publication of MX2021016049A publication Critical patent/MX2021016049A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta solicitud se refiere a los inhibidores de RAD51 que están representados por la siguiente fórmula estructural: (ver formula); y a los métodos para usarlos, tal como para el tratamiento del cáncer de páncreas.
MX2021016049A 2019-06-21 2020-06-22 Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas. MX2021016049A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864861P 2019-06-21 2019-06-21
US201962895138P 2019-09-03 2019-09-03
PCT/US2020/038895 WO2020257752A1 (en) 2019-06-21 2020-06-22 Methods of using rad51 inhibitors for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2021016049A true MX2021016049A (es) 2022-02-03

Family

ID=71528072

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021016049A MX2021016049A (es) 2019-06-21 2020-06-22 Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.

Country Status (12)

Country Link
US (1) US12064419B2 (es)
EP (1) EP3986402A1 (es)
JP (1) JP2022537372A (es)
KR (1) KR20220024857A (es)
CN (1) CN114514023A (es)
AU (1) AU2020296195A1 (es)
BR (1) BR112021025491A2 (es)
CA (1) CA3143716A1 (es)
IL (1) IL288707A (es)
MX (1) MX2021016049A (es)
TW (1) TW202114662A (es)
WO (1) WO2020257752A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11607404B2 (en) 2019-03-25 2023-03-21 Cyteir Therapeutics, Inc. Combinations of RAD51 and PARP inhibitors
EP4114389A1 (en) * 2020-03-03 2023-01-11 Cyteir Therapeutics, Inc. The rad51 inhibitor compound 67a (2301085-06-1) at a specific dosage for treating cancer
WO2023078271A1 (zh) * 2021-11-02 2023-05-11 上海旭成医药科技有限公司 芳香化合物、其制备方法、中间体、药物组合物和应用
WO2023211938A1 (en) * 2022-04-25 2023-11-02 Cyteir Therapeutics, Inc. Methods of using a (thiazolyl)benzenesulfonamide derivative
WO2023211945A1 (en) * 2022-04-25 2023-11-02 Cyteir Therapeutics, Inc. Methods of using a (thiazolyl)benzenesulfonamide derivative
WO2024086735A1 (en) * 2022-10-19 2024-04-25 Cyteir Therapeutics, Inc. Methods of using a (thiazolyl) benzenesulfonamide derivative
CN117603097B (zh) * 2023-11-29 2024-06-18 安徽泽升科技股份有限公司 一种快速制备2-溴-5-硝基苯磺酰氯的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
DE69132843T2 (de) 1990-12-06 2002-09-12 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Identifizierung von Nukleinsäuren in Proben
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US10912761B2 (en) * 2012-11-30 2021-02-09 The University Of Chicago Methods and compositions involving RAD51 inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US10973819B2 (en) 2016-03-02 2021-04-13 The University Of Chicago Small molecules inhibitors of RAD51
EP3652159B1 (en) 2017-07-11 2023-01-18 Cyteir Therapeutics, Inc. Substituted thiazole derivatives as rad51 inhibitors for the treatment of cancer diseases, autoimmune and neurodegenerative conditions
HUE059969T2 (hu) * 2017-09-11 2023-01-28 Cyteir Therapeutics Inc RAD51 inhibitorok
TW202104198A (zh) 2019-03-12 2021-02-01 美商賽堤爾醫療公司 Ｒａｄ５１抑制劑
US11607404B2 (en) * 2019-03-25 2023-03-21 Cyteir Therapeutics, Inc. Combinations of RAD51 and PARP inhibitors

Also Published As

Publication number Publication date
US20200397760A1 (en) 2020-12-24
EP3986402A1 (en) 2022-04-27
AU2020296195A1 (en) 2022-01-20
IL288707A (en) 2022-02-01
CN114514023A (zh) 2022-05-17
US12064419B2 (en) 2024-08-20
CA3143716A1 (en) 2020-12-24
TW202114662A (zh) 2021-04-16
KR20220024857A (ko) 2022-03-03
JP2022537372A (ja) 2022-08-25
WO2020257752A1 (en) 2020-12-24
BR112021025491A2 (pt) 2022-04-26

Similar Documents

Publication Publication Date Title
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2021010916A (es) Inhibidores rad51.
SA520420458B1 (ar) نظائر رابامايسين مرتبطة بـ C40، C28، وC32 mTOR كمثبطات
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
JOP20210154B1 (ar) مثبطات kif18a
MX2021007104A (es) Inhibidores de kif18a.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2023004221A (es) Inhibidores de rad51.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
EA201591382A1 (ru) Ингибиторы гистондеметилаз
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MX2020000367A (es) Inhibidores de rad51.
MX2022001004A (es) Inhibidores de enzimas.
MX2021011689A (es) Combinaciones de inhibidores de rad51 y parp.
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2024002391A (es) Inhibidores de indolina de kif18a.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2022002069A (es) Inhibidores de enzimas.